Grace Therapeutics (GRCE) Net Income (2019 - 2026)

Grace Therapeutics has disclosed Net Income across 8 years of filings, most recently posting -$15.8 million for Q2 2026.

• In Q2 2026, Net Income fell 369.66% year-over-year to -$15.8 million; the TTM figure through Jun 2026 stood at -$19.9 million (down 93.23% YoY), while the FY2026 annual figure was -$7.5 million, up 21.61% from the prior year.
• Net Income came in at -$15.8 million for Q2 2026 at Grace Therapeutics, down from -$885000.0 in the prior quarter.
• In the past five years, Net Income ranged from a high of $636000.0 in Q1 2025 to a low of -$24.9 million in Q1 2023.
• Average Net Income over 5 years is -$4.7 million, with a median of -$3.3 million recorded in 2023.
• Year-over-year, Net Income tumbled 1298.03% in 2023 and jumped 133.23% in 2025.
• Over 5 years, Net Income stood at -$3.9 million in 2022, then jumped by 38.52% to -$2.4 million in 2023, then tumbled by 73.78% to -$4.2 million in 2024, then soared by 44.28% to -$2.3 million in 2025, then tumbled by 582.07% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$15.8 million in Q2 2026, -$885000.0 in Q1 2026, and -$2.3 million in Q4 2025.